Related Searches: Tea Vitamin Nutrients Ingredients paper cup packing

Food & Health Ingredients
Health & Nutrition
Processing & Packaging
Starch & Starch Derivatives

Lonza to set up biologics facility in China

ingredientsnetwork 2018-12-14
Share       

Lonza has announced an agreement with GE Healthcare under which GE Healthcare will deliver a biologics facility to Lonza in Guangzhou, China. As the facility is part of a larger biomanufacturing initiative between GE Healthcare and Guangzhou Development District (GDD), the agreement will be finalized when contracts have been signed with the GDD.

 

By working with GE Healthcare to develop the new facility, based on the KUBio platform, an off-the-shelf biologics factory, Lonza intends to offer its suite of antibody development services and manufacture GMP-certified batches by 2020. The two companies will work closely on the design of the 17,000m2 site, which will include 6,500m2 of lab space and one KUBio facility.

 

The labs will house Lonza’s proprietary platforms for cell-line construction, including the GS Gene expression System, as well as process development, cell banking and pilot labs. The KUBio unit will enable small-scale GMP manufacturing equipped with GE Healthcare’s single-use biomanufacturing technologies, including 1,000 and 2,000L bioreactors, combined with Lonza’s automation platforms for clinical and early-commercial supply.

 

“This partnership is the ideal way for Lonza to bring our expertise and technology to China,” said Marc Funk, COO Lonza Pharma & Biotech. “The combination of a strong and experienced technology provider with a long history in China, together with a dynamic regional authority, means that we can rapidly offer services to customers and ultimately get innovative therapies to patients more quickly.”

 

GE Healthcare is working with the GDD to support large-scale manufacturing of biopharmaceuticals in China.

 

“With Lonza coming on site, a hub of biotech is truly taking shape,” said Emmanuel Ligner, President and CEO, GE Healthcare Life Sciences. “This agreement is yet another step in realizing our vision of enabling and supporting manufacturers of all sizes to quickly deploy capacity and meet increasing customer demand for biologics.”

 

The facility in China will extend Lonza Pharma & Biotech’s global biologics network that provides development and manufacturing services from gene through IND and BLA to mature commercial supply. In addition to the new Chinese site, the network comprises small-, mid- and large-scale assets in Switzerland, the United States, the UK, Spain and Singapore.

 

Lonza plans to hire and train more than 160 staff, and the new site will benefit from the company’s global standards of technological and operational excellence. With more than 20 successful FDA approvals for biologics, combined with international regulatory expertise, Lonza will now be able to offer the same high standards in China as it does elsewher.

E-newsletter

Subscribe to our e-newsletter for the latest food ingredients news and trends.

Tags

Recommended Products

Potato starch equipment

Potato starch equipment

Vermicelli series45A

Vermicelli series45A

Collagen peptide solid drink

Collagen peptide solid drink

packing strap 2R2A9567

packing strap 2R2A9567

RC2M Roller Conveyor

RC2M Roller Conveyor

Top

SJGLE B2B Website : 中文版 | ChineseCustomer Service: 86-400 610 1188-3 ( Mon-Fri 9: 00-18: 00 BJT)

About Us|Contact Us|Privacy Policy|Intellectual Property Statement

Copyright 2006-2023 Shanghai Sinoexpo Informa Markets International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-121